Prognostic index for younger adults with AML in relapse
| Risk . | Index score in points . | Survival probability, % . | |
|---|---|---|---|
| at 1 y . | at 5 y . | ||
| Favorable (9% of patients) | 0-6 | 70 | 46 |
| Intermediate (25% of patients) | 7-9 | 49 | 18 |
| Unfavorable (66% of patients) | 10-14 | 16 | 4 |
| Risk . | Index score in points . | Survival probability, % . | |
|---|---|---|---|
| at 1 y . | at 5 y . | ||
| Favorable (9% of patients) | 0-6 | 70 | 46 |
| Intermediate (25% of patients) | 7-9 | 49 | 18 |
| Unfavorable (66% of patients) | 10-14 | 16 | 4 |
Evaluated in patients 15 to 60 years234 ; APL with t(15;17) excluded; prognostic relapse score is estimated according to the following factors:
Duration of remission prior to relapse: > 18 months (0 points); 7 to 18 months (3 points); and 6 months or less (5 points).
Cytogenetics at initial diagnosis: inv(16) or t(16;16) (0 points); t(8;21) (3 points); other (5 points).
Prior hematopoietic stem cell transplantation: no (0 points); yes (2 points).
Age at time of relapse: 35 years or less (0 points); 36 to 45 years (1 point); more than 45 years (2 points).